{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981469849453440.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1093/jac/39.4.471"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/jac/article-pdf/39/4/471/9837633/390471.pdf"}},{"identifier":{"@type":"PMID","@value":"9145819"}}],"dc:title":[{"@value":"Comparative studies of the bactericidal, morphological and post- antibiotic effects of arbekacin and vancomycin against methicillin- resistant Staphylococcus aureus"}],"description":[{"notation":[{"@value":"Arbekacin, an aminoglycoside antibiotic, has antibacterial activity against both Gram-positive and Gram-negative bacteria and is stable in the presence of aminoglycoside-inactivating enzymes produced by methicillin-resistant Staphylococcus aureus (MRSA). In this report, the antibacterial activity of arbekacin was compared with that of vancomycin, a glycopeptide antibiotic that also has potent antibacterial activity against MRSA. Arbekacin showed concentration-dependent bactericidal activity against MRSA strain 1936 (0.5-2 x MIC), but vancomycin showed only slight bactericidal activity, even at high concentrations of 19 x MIC. Arbekacin showed a longer post-antibiotic effect (2.3-3.8 h) than vancomycin (0-1.3 h) against MRSA strain 1936. Arbekacin induced marked morphological changes at 0.5 x MIC and the changes remained for 2 h after removal of the agent. When exposed to 0.5 x MIC of vancomycin, no notable morphological change was observed in the treated cells. Since arbekacin has broad-spectrum activity, these findings suggest that it may be a useful agent against MRSA infection, especially for polymicrobial MRSA infection with Gram-negative bacilli, such as Pseudomonas aeruginosa."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981469849453440","@type":"Researcher","foaf:name":[{"@value":"T Watanabe"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"14602091"}],"prism:publicationName":[{"@value":"Journal of Antimicrobial Chemotherapy"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"1997-04-01","prism:volume":"39","prism:number":"4","prism:startingPage":"471","prism:endingPage":"476"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://academic.oup.com/jac/article-pdf/39/4/471/9837633/390471.pdf"}],"createdAt":"2002-07-26","modifiedAt":"2017-08-23","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Staphylococcus%20aureus","dc:title":"Staphylococcus aureus"},{"@id":"https://cir.nii.ac.jp/all?q=Dose-Response%20Relationship,%20Drug","dc:title":"Dose-Response Relationship, Drug"},{"@id":"https://cir.nii.ac.jp/all?q=Dibekacin","dc:title":"Dibekacin"},{"@id":"https://cir.nii.ac.jp/all?q=Microbial%20Sensitivity%20Tests","dc:title":"Microbial Sensitivity Tests"},{"@id":"https://cir.nii.ac.jp/all?q=Anti-Bacterial%20Agents","dc:title":"Anti-Bacterial Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Aminoglycosides","dc:title":"Aminoglycosides"},{"@id":"https://cir.nii.ac.jp/all?q=Vancomycin","dc:title":"Vancomycin"},{"@id":"https://cir.nii.ac.jp/all?q=Methicillin%20Resistance","dc:title":"Methicillin Resistance"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285707260063616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205048121984","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"新しい推奨ピーク値を目標とした新生児に対するアルベカシン 1 日1 回投与法の検討"},{"@language":"en","@value":"Evaluation of Once a Day of Arbekacin Administration to Neonates as a New Object of Peak Concentration"},{"@language":"ja-Kana","@value":"アタラシイ スイショウ ピークチ オ モクヒョウ ト シタ シンセイジ ニ タイスル アルベカシン 1ニチ 1カイ トウヨホウ ノ ケントウ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/jac/39.4.471"},{"@type":"OPENAIRE","@value":"doi_dedup___::0d85e733072b8be11bbd894c59ee242e"},{"@type":"CROSSREF","@value":"10.1016/j.jiac.2013.12.005_references_DOI_RE8U74w4dNNfrrRcpOt3ECPYrGo"},{"@type":"CROSSREF","@value":"10.11150/kansenshogakuzasshi.84.727_references_DOI_RE8U74w4dNNfrrRcpOt3ECPYrGo"}]}